Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus.
1999; National Institutes of Health; Volume: 5; Issue: 6 Linguagem: Inglês
Autores
Jodi D. Bradley, Yuki Kataoka, Sunil J. Advani, S M Chung, Ramin B. Arani, G. Yancey Gillespie, R. J. Whitley, James M. Markert, Bernard Roizman, Ralph R. Weichselbaum,
Tópico(s)CAR-T cell therapy research
ResumoMalignant gliomas remain incurable with current interventions. Encouraging investigational approaches include the use of genetically modified herpes simplex-1 (HSV-1) viruses as direct cytotoxic agents. Combining attenuated HSV-1 with standard therapy, human U-87 malignant glioma xenografts grown in the hind limb or intracranially in athymic nude mice were exposed to ionizing radiation, inoculated with genetically modified HSV R3616, or received both virus and radiation. The combination of virus with fractionated ionizing radiation suggests a synergistic action and results in reduced tumor volumes and longer survivals when compared with treatment with either modality alone.
Referência(s)